Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rivoceranib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 17/20 | 0.91 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 1.00 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.58 |
| ▸ | CIT | O14578 | 1/20 | 0.55 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.55 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.55 |
| ▸ | STK10 | O94804 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | RAF1 | P04049 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | FYN | P06241 | 1/20 | 0.55 |
| ▸ | CSF1R | P07333 | 1/20 | 0.55 |
| ▸ | YES1 | P07947 | 1/20 | 0.55 |
| ▸ | LYN | P07948 | 1/20 | 0.55 |
| ▸ | HCK | P08631 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rivoceranib SCHEMBL1814966 | 1.00 | RET (1.00) | RETMAP3K20RIPK3KDRABCB1 | |
| SCHEMBL6014666 | 0.99 | RET (0.98) | RETMAP3K20RIPK3KDRABCB1 | |
| SCHEMBL6014575 | 0.98 | RET (0.96) | RETMAP3K20RIPK3KDRABCB1 | |
| SCHEMBL6014552 | 0.96 | RET (0.93) | RETMAP3K20RIPK3KDRABCB1 | |
| Rivoceranib SCHEMBL21847695 | 0.96 | KDR (1.00) | RETMAP3K20RIPK3KDRABCB1 | |
| SCHEMBL31362718 | 0.93 | RET (0.88) | RETMAP3K20RIPK3KDRABCB1 | |
| SCHEMBL31362698 | 0.91 | RET (0.83) | RETMAP3K20RIPK3KDRABCB1 | |
| SCHEMBL31362733 | 0.91 | RET (0.83) | RETMAP3K20RIPK3KDRABCB1 | |
| SCHEMBL6014673 | 0.87 | RET (0.76) | RETMAP3K20RIPK3KDRABL1 | |
| SCHEMBL6014721 | 0.86 | RET (0.75) | RETMAP3K20RIPK3KDRABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2785 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| US-12636323-B2 | Use of Clostridium ghonii combined with tumor angiogenesis inhibitor | SHIHUIDA PHARMACEUTICAL GROUP (JILIN) CO., LTD. (CN) | 2026-05-26 | — | — | US | claimed |
| CN-122075677-A | GM-CSF loaded tumor cell vaccine and application thereof in preventing and treating liver cancer | — | 2026-05-26 | — | — | CN | claimed |
| US-12630624-B2 | Anti-IL-27 antibodies and uses thereof | Surface Oncology, LLC (US) | 2026-05-19 | — | — | US | claimed |
| CN-122055366-A | GCN2 and PERK kinase modulators and methods of use thereof | 德西费拉制药有限责任公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| CN-122029214-A | Phospholipid drug conjugate and preparation method and application thereof | 上海弼领生物技术有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260124318-A1 | POLYMERIC MATERIAL AND PREPARATION METHOD THEREOF, AND DRUG-LOADING MATERIAL | SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2026-05-07 | — | — | US | claimed |
| US-20260115237-A1 | PROBIOTIC COMPOSITION FOR PREVENTING AND TREATING ANTI-TUMOR TREATMENT-RELATED DIARRHEA AND USE THEREOF | SICHUAN ANAEROBIC BIOTECHNOLOGY CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| CN-114028393-A | Application of apatinib in preparation of medicine for treating multiple sclerosis | 天津医科大学 | 2022-02-11 | — | — | CN | claimed |
| CN-114028586-A | Method for researching antitumor effect of apatinib based on PDX model | 南昌大学附属口腔医院(江西省口腔医院) | 2022-02-11 | — | — | CN | claimed |
| CN-111558044-B | Pharmaceutical composition containing sunitinib, and preparation and application thereof | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2022-02-11 | — | — | CN | claimed |
| CN-111789895-B | External traditional Chinese medicine composition for treating hand-foot skin reaction | 中日友好医院 | 2022-02-11 | — | — | CN | claimed |
| CN-114028568-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| WO-2022026510-A1 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB, A TAXANE, AND A VEGFR-2 ANTAGONIST | SEAGEN INC. (US) | 2022-02-03 | — | — | WO | claimed |
| CN-113975264-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-01-28 | — | — | CN | claimed |
| WO-2022020648-A1 | INHIBITORS OF THE ARTEMIN PATHWAY FOR TREATMENT OF CANCER | THE UNIVERSITY OF CHICAGO (US) | 2022-01-27 | — | — | WO | claimed |
| WO-2022016844-A1 | INTERFERON-BASED CANCER TREATMENT METHOD AND PHARMACEUTICAL COMPOSITION | 厦门特宝生物工程股份有限公司 | 2022-01-27 | — | — | WO | claimed |